Clinical Trial

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-28; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2025-08-01
Trial Details
NCT Number NCT06959550
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Akesobio Australia Pty Ltd, Summit Therapeutics
Conditions Metastatic Colorectal Cancer
Enrollment 90 participants
Start Date 2025-07-28
Primary Completion 2028-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20